{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:38:54Z","timestamp":1785411534803,"version":"3.56.0"},"reference-count":20,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013043","name":"Ariel University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013043","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/03nz8qe97","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background: Malignant prostate cancer (PrC) remains challenging to treat due to tumor heterogeneity and the limited availability of ligands that target disease-associated surface markers with properties appropriate for targeted drug delivery systems. To overcome this hurdle, we used an unbiased but stringent selection strategy to discover a series of phage-displayed peptides that internalize specifically into PrC tumors. Methods: Here we report the characteristics, properties and function of one of these peptides, Pr10, and validate its ability to specifically deliver cytotoxic drugs into PrC cells and kill them, both in vitro and in xenograft models. Results: Biochemical and proteomic studies identified the receptor for Pr10 as Desmocollin-3 (DSC3). This finding was confirmed by demonstrating the expression of the DSC-3 protein on PrC cells; by siRNA knockdown of DSC3 expression, which abrogated Pr10 function; and by in silico docking experiments. Conclusions: Together, these findings identify DSC3 as a novel, functional receptor on malignant prostate cancer cells and establish Pr10 as an effective and PrC-selective ligand for drug delivery PrC cells. More broadly, this work highlights the ability of unbiased screening approaches to identify and isolate novel target receptors with properties appropriate for use in effective target drug delivery systems for cancer therapy.<\/jats:p>","DOI":"10.3390\/pharmaceutics18070802","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T10:01:17Z","timestamp":1782813677000},"page":"802","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Desmocollin-3 Is a Novel Target Receptor for Targeted Drug Delivery for Malignant Prostate Cancer"],"prefix":"10.3390","volume":"18","author":[{"given":"Vipin","family":"Sharma","sequence":"first","affiliation":[{"name":"Laboratory for Immunology and Cancer Biology, Department of Chemical Engineering, Adelson School of Medicine, Ariel University, Ariel 40700, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Lohiya","sequence":"additional","affiliation":[{"name":"Laboratory for Immunology and Cancer Biology, Department of Chemical Engineering, Adelson School of Medicine, Ariel University, Ariel 40700, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanni Grace","family":"Francis","sequence":"additional","affiliation":[{"name":"Laboratory for Immunology and Cancer Biology, Department of Chemical Engineering, Adelson School of Medicine, Ariel University, Ariel 40700, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3977-3989","authenticated-orcid":false,"given":"Galia","family":"Luboshits","sequence":"additional","affiliation":[{"name":"Laboratory for Immunology and Cancer Biology, Department of Chemical Engineering, Adelson School of Medicine, Ariel University, Ariel 40700, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1125-2751","authenticated-orcid":false,"given":"Dror","family":"Tobi","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology, Ariel University, Ariel 40700, Israel"},{"name":"Department of Computer Science, Ariel University, Ariel 40700, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8430-0486","authenticated-orcid":false,"given":"Michael A.","family":"Firer","sequence":"additional","affiliation":[{"name":"Laboratory for Immunology and Cancer Biology, Department of Chemical Engineering, Adelson School of Medicine, Ariel University, Ariel 40700, Israel"},{"name":"Adelson School of Medicine, Ariel University, Ariel 40700, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jama.2025.0228","article-title":"Prostate Cancer: A Review","volume":"333","author":"Raychaudhuri","year":"2025","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"117829","DOI":"10.1016\/j.ejmech.2025.117829","article-title":"PSMA Targeted Therapy: From Molecular Mechanisms to Clinical Breakthroughs in Castration-Resistant Prostate Cancer","volume":"296","author":"Wang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"107402","DOI":"10.1016\/j.jddst.2025.107402","article-title":"Advances in Targeted Drug Delivery Systems for Cancer Treatment: Current Trends and Future Prospects","volume":"113","author":"Khan","year":"2025","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.3390\/ijms22041551","article-title":"Treating Prostate Cancer by Antibody-Drug Conjugates","volume":"22","author":"Rosellini","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"122469","DOI":"10.1016\/j.biomaterials.2024.122469","article-title":"Nanotherapeutics for Prostate Cancer Treatment: A Comprehensive Review","volume":"305","author":"Hu","year":"2024","journal-title":"Biomaterials"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41585-025-01014-w","article-title":"Targeting the Tumour Cell Surface in Advanced Prostate Cancer","volume":"22","author":"Boixareu","year":"2025","journal-title":"Nat. Rev. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"7286","DOI":"10.3390\/curroncol30080529","article-title":"PSMA Targeted Molecular Imaging and Radioligand Therapy for Prostate Cancer: Optimal Patient and Treatment Issues","volume":"30","author":"Hoshi","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_8","first-page":"927","article-title":"Monoclonal Antibodies to a New Antigenic Marker in Epithelial Prostatic Cells and Serum of Prostatic Cancer Patients","volume":"7","author":"Horoszewicz","year":"1987","journal-title":"Anticancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.canlet.2017.08.040","article-title":"Discovery of Peptide Drug Carrier Candidates for Targeted Multi-Drug Delivery into Prostate Cancer Cells","volume":"408","author":"Bashari","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Cohen, A., Kashkoosh, M., Sharma, V., Panja, A., Shpitzer, S.A., Golan, S., Bazylevich, A., Gellerman, G., Luboshits, G., and Firer, M.A. (2025). Applying Unbiased, Functional Criteria Allows Selection of Novel Cyclic Peptides for Effective Targeted Drug Delivery to Malignant Prostate Cancer Cells. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17070866"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"18091","DOI":"10.1038\/s41598-022-22788-8","article-title":"Expression of Membrane Hsp90 Is a Molecular Signature of T Cell Activation","volume":"12","author":"Scarneo","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1091\/mbc.e03-08-0596","article-title":"Association with Membrane Protrusions Makes ErbB2 an Internalization-Resistant Receptor","volume":"15","author":"Hommelgaard","year":"2004","journal-title":"Mol. Biol. Cell"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Pan, J., Chen, Y., Mo, C., Wang, D., Chen, J., Mao, X., Guo, S., Zhuang, J., and Qiu, S. (2014). Association of DSC3 MRNA Down-Regulation in Prostate Cancer with Promoter Hypermethylation and Poor Prognosis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0092815"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Cui, Y., and Yamada, S. (2013). N-Cadherin Dependent Collective Cell Invasion of Prostate Cancer Cells Is Regulated by the N-Terminus of \u03b1-Catenin. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0055069"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.2147\/CMAR.S389825","article-title":"Cofilin Acts as a Booster for Progression of Malignant Tumors Represented by Glioma","volume":"14","author":"Lv","year":"2022","journal-title":"Cancer Manag. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1126\/science.1071559","article-title":"C-Cadherin Ectodomain Structure and Implications for Cell Adhesion Mechanisms","volume":"296","author":"Boggon","year":"2002","journal-title":"Science"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/onc.2016.237","article-title":"Cadherin-6 Promotes EMT and Cancer Metastasis by Restraining Autophagy","volume":"36","author":"Gugnoni","year":"2017","journal-title":"Oncogene"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"151220","DOI":"10.1016\/j.ejcb.2022.151220","article-title":"Multiple Roles for Basement Membrane Proteins in Cancer Progression and EMT","volume":"101","author":"Banerjee","year":"2022","journal-title":"Eur. J. Cell Biol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Deandreis, D., and Deutsch, E. (2026). New Paradigms in Theranostics of Prostate Cancer: The Rise of \u03b1-Emitters and Next-Generation Targets. Eur. Urol. Focus, in press.","DOI":"10.1016\/j.euf.2026.05.015"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.cpet.2026.02.003","article-title":"Novel Theranostic Targets for Prostate Cancer Beyond Prostate-Specific Membrane Antigen","volume":"21","author":"Heidari","year":"2026","journal-title":"PET Clin."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/7\/802\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T04:16:03Z","timestamp":1783052163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/7\/802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":20,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["pharmaceutics18070802"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18070802","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]}}}